CD4 and type 2 diabetes mellitus: Increases in the percentage of S-reactive CD4+ TSCM cells were observed in participants with type 2 diabetes after their first dose of BNT162b2, but this difference was no longer observed after the second dose (Figure 4F; Supplementary Figure 8C).